Farallon Capital Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Farallon Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-200,000	Closed	-$1.72M	–	120
2015 Q1	$1.72M	Sell	200,000 -100,000	-33%	-$894K	0.03%	87
2014 Q4	$2.99M	Sell	300,000 -400,000	-57%	-$3.41M	0.04%	80
2014 Q3	$6.93M	Hold	700,000	–	–	0.11%	73
2014 Q2	$12.1M	Hold	700,000	–	–	0.17%	64
2014 Q1	$12.4M	Hold	700,000	–	–	0.24%	57
2013 Q4	$12.8M	Buy	700,000 +230,000	+49%	+$4.34M	0.27%	55
2013 Q3	$12.6M	Buy	470,000 +42,000	+10%	+$900K	0.26%	52
2013 Q2	$7.9M	Buy	+428,000	New	+$7.56M	0.15%	59

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DCM

Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

Farallon Capital Management's RPRX Position: Q2 2015 in Review

Farallon Capital Management sold out of Repros Therapeutics Inc. (RPRX) in Q2 2015, closing a stake of 200,000 shares — an estimated $1.72M sold.

Farallon Capital Management first reported a position in RPRX in Q2 2013 and held it in 8 quarters. The position peaked at $12.8M in Q4 2013. 64 funds tracked by Wall St. Rank hold RPRX as of Q2 2015.

Farallon Capital Management reported no remaining Repros Therapeutics Inc. position as of Q2 2015 after selling out during the quarter.
Farallon Capital Management sold 200,000 Repros Therapeutics Inc. shares in Q2 2015, an estimated $1.72M.
Farallon Capital Management first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 8 quarters.
Farallon Capital Management's Repros Therapeutics Inc. position peaked at $12.8M in Q4 2013.
64 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2015.

Based on Farallon Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.